Corinne Vigouroux

List of Publications by Year
in descending order

97	6,425	87888 38	66911 78
papers	citations	h-index	g-index

103	103	103	6348
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification of the gene altered in Berardinelliâ€“Seip congenital lipodystrophy on chromosome 11q13. Nature Genetics, 2001, 28, 365-370.	21.4	665
2	Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet, The, 2002, 359, 1026-1031.	13.7	377
3	The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4500-4511.	3.6	323
4	The HIV Protease Inhibitor Indinavir Impairs Sterol Regulatory Element-Binding Protein-1 Intranuclear Localization, Inhibits Preadipocyte Differentiation, and Induces Insulin Resistance. Diabetes, 2001, 50, 1378-1388.	0.6	307
5	Seipin regulates <scp>ER</scp>â€“lipid droplet contacts and cargo delivery. EMBO Journal, 2016, 35, 2699-2716.	7.8	258
6	Perilipin Deficiency and Autosomal Dominant Partial Lipodystrophy. New England Journal of Medicine, 2011, 364, 740-748.	27.0	248
7	Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Molecular Medicine, 2009, 1, 280-287.	6.9	235
8	Nuclear envelope disorganization in fibroblasts from lipodystrophic patients with heterozygous R482Q/W mutations in the lamin A/C gene. Journal of Cell Science, 2001, 114, 4459-4468.	2.0	219
9	A New Clinical Condition Linked to a Novel Mutation in Lamins A and C with Generalized Lipoatrophy, Insulin-Resistant Diabetes, Disseminated Leukomelanodermic Papules, Liver Steatosis, and Cardiomyopathy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1006-1013.	3.6	186
10	Nuclear envelope disorganization in fibroblasts from lipodystrophic patients with heterozygous R482Q/W mutations in the lamin A/C gene. Journal of Cell Science, 2001, 114, 4459-68.	2.0	186
11	Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. Cell Death and Differentiation, 2007, 14, 1759-1767.	11.2	182
12	Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Diabetes, 2000, 49, 1958-1962.	0.6	165
13	HIV-associated lipodystrophy: from fat injury to premature aging. Trends in Molecular Medicine, 2010, 16, 218-229.	6.7	163
14	PIK3R1 Mutations Cause Syndromic Insulin Resistance with Lipoatrophy. American Journal of Human Genetics, 2013, 93, 141-149.	6.2	162
15	Chrom3D: three-dimensional genome modeling from Hi-C and nuclear lamin-genome contacts. Genome Biology, 2017, 18, 21.	8.8	159
16	New Metabolic Phenotypes in Laminopathies:LMNAMutations in Patients with Severe Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4835-4844.	3.6	136
17	Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. Circulation, 2019, 140, 293-302.	1.6	131
18	Molecular mechanisms of human lipodystrophies: From adipocyte lipid droplet to oxidative stress and lipotoxicity. International Journal of Biochemistry and Cell Biology, 2011, 43, 862-876.	2.8	120

#	Article	IF	Citations
19	Expression of Lamin A Mutated in the Carboxyl-Terminal Tail Generates an Aberrant Nuclear Phenotype Similar to That Observed in Cells from Patients with Dunnigan-Type Partial Lipodystrophy and Emery-Dreifuss Muscular Dystrophy. Experimental Cell Research, 2003, 282, 14-23.	2.6	106
20	Patients with Familial Partial Lipodystrophy of the Dunnigan Type Due to aLMNAR482W Mutation Show Muscular and Cardiac Abnormalities. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5337-5346.	3.6	106
21	Laminopathies disrupt epigenomic developmental programs and cell fate. Science Translational Medicine, 2016, 8, 335ra58.	12.4	91
22	Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opinion on Drug Safety, 2019, 18, 829-840.	2.4	86
23	Fertility and Obstetrical Complications in Women withLMNA-Related Familial Partial Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2223-2229.	3.6	80
24	Type A Insulin Resistance Syndrome Revealing a Novel Lamin A Mutation. Diabetes, 2005, 54, 1873-1878.	0.6	75
25	HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie, 2005, 87, 65-71.	2.6	72
26	Lipodystrophy-Linked LMNA p.R482W Mutation Induces Clinical Early Atherosclerosis and In Vitro Endothelial Dysfunction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2162-2171.	2.4	69
27	Premature Senescence of Vascular Cells Is Induced by HIV Protease Inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2611-2620.	2.4	67
28	Inappropriately Low Glycated Hemoglobin Values and Hemolysis in HIV-Infected Patients. AIDS Research and Human Retroviruses, 2006, 22, 1242-1247.	1.1	60
29	Nuclear envelope-related lipodystrophies. Seminars in Cell and Developmental Biology, 2014, 29, 148-157.	5.0	58
30	LMNA Mutations Induce a Non-Inflammatory Fibrosis and a Brown Fat-Like Dystrophy of Enlarged Cervical Adipose Tissue. American Journal of Pathology, 2011, 179, 2443-2453.	3.8	57
31	The p.R482W substitution in A-type lamins deregulates SREBP1 activity in Dunnigan-type familial partial lipodystrophy. Human Molecular Genetics, 2015, 24, 2096-2109.	2.9	57
32	Higher Adiponectin Levels in Patients with Berardinelli-Seip Congenital Lipodystrophy due to Seipin as compared with 1-Acylglycerol-3-Phosphate-O-Acyltransferase-2 Deficiency. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1463-1468.	3.6	54
33	Peroxisome Proliferator-Activated Receptor-Î³ Mutations Responsible for Lipodystrophy With Severe Hypertension Activate the Cellular Reninâ€“Angiotensin System. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 829-838.	2.4	53
34	MFN2-associated lipomatosis: Clinical spectrum and impact on adipose tissue. Journal of Clinical Lipidology, 2018, 12, 1420-1435.	1.5	47
35	Oneâ€year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes. Diabetes, Obesity and Metabolism, 2016, 18, 693-697.	4.4	46
36	LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: Role of ZMPSTE24 downregulation. Atherosclerosis, 2016, 245, 200-211.	0.8	45

#	Article	IF	Citations
37	Partial lipodystrophy with severe insulin resistance and adult progeria Werner syndrome. Orphanet Journal of Rare Diseases, 2013, 8, 106.	2.7	43
38	Functional Human Beige Adipocytes From Induced Pluripotent Stem Cells. Diabetes, 2017, 66, 1470-1478.	0.6	42
39	A Homozygous Mutation of Prelamin-A Preventing Its Farnesylation and Maturation Leads to a Severe Lipodystrophic Phenotype: New Insights into the Pathogenicity of Nonfarnesylated Prelamin-A. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E856-E862.	3.6	39
40	Extracellular matrix remodeling and transforming growth factor-Î² signaling abnormalities induced by lamin A/C variants that cause lipodystrophy. Journal of Lipid Research, 2017, 58, 151-163.	4.2	38
41	The lipodystrophic hotspot lamin A p.R482W mutation deregulates the mesodermal inducer T/Brachyury and early vascular differentiation gene networks. Human Molecular Genetics, 2018, 27, 1447-1459.	2.9	34
42	Progerin Expression Induces Inflammation, Oxidative Stress and Senescence in Human Coronary Endothelial Cells. Cells, 2020, 9, 1201.	4.1	34
43	Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes. Diabetes Care, 2019, 42, 2008-2010.	8.6	33
44	A Novel Lamin A Mutant Responsible for Congenital Muscular Dystrophy Causes Distinct Abnormalities of the Cell Nucleus. PLoS ONE, 2017, 12, e0169189.	2.5	32
45	Seipin localizes at endoplasmic-reticulum-mitochondria contact sites to control mitochondrial calcium import and metabolism in adipocytes. Cell Reports, 2022, 38, 110213.	6.4	29
46	Antiretroviral-Related Adipocyte Dysfunction and Lipodystrophy in HIV-Infected Patients: Alteration of the PPARÎ³-Dependent Pathways. PPAR Research, 2009, 2009, 1-8.	2.4	28
47	Diagnostic Challenge in PLIN1-Associated Familial Partial Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6025-6032.	3.6	28
48	Deregulation of Fragile X-related protein 1 by the lipodystrophic lamin A p.R482W mutation elicits a myogenic gene expression program in preadipocytes. Human Molecular Genetics, 2014, 23, 1151-1162.	2.9	27
49	Metabolic and cardiac phenotype characterization in 37 atypical Dunnigan patients with nonfarnesylated mutated prelamin A. American Heart Journal, 2015, 169, 587-593.	2.7	25
50	Lipodystrophic syndromesÂdue to LMNA mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives. Nucleus, 2018, 9, 251-264.	2.2	25
51	Metabolic risk factors in young adults infected with HIV since childhood compared with the general population. PLoS ONE, 2018, 13, e0206745.	2.5	24
52	What the Genetics of Lipodystrophy Can Teach Us About Insulin Resistance and Diabetes. Current Diabetes Reports, 2013, 13, 757-767.	4.2	23
53	Molecular and Cellular Bases of Lipodystrophy Syndromes. Frontiers in Endocrinology, 2021, 12, 803189.	3.5	23
54	Cardiometabolic assessment of lamin A/C gene mutation carriers: a phenotypeâ€“genotype correlation. Diabetes and Metabolism, 2019, 45, 382-389.	2.9	22

#	Article	IF	Citations
55	Bone imaging findings in genetic and acquired lipodystrophic syndromes: an imaging study of 24 cases. Skeletal Radiology, 2016, 45, 1495-1506.	2.0	21
56	European lipodystrophy registry: background and structure. Orphanet Journal of Rare Diseases, 2020, 15, 17.	2.7	21
57	Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases. Current Medical Research and Opinion, 2019, 35, 543-552.	1.9	20
58	Lipodystrophic syndromes: From diagnosis to treatment. Annales D'Endocrinologie, 2020, 81, 51-60.	1.4	20
59	Antiinsulin Receptor Autoantibodies Induce Insulin Receptors to Constitutively Associate with Insulin Receptor Substrate-1 and -2 and Cause Severe Cell Resistance to Both Insulin and Insulin-Like Growth Factor I¹. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3197-3206.	3.6	19
60	Type B Insulin-resistance syndrome: a cause of reversible autoimmune hypoglycaemia. Lancet, The, 2014, 384, 1548.	13.7	19
61	HIV-mediated immune aging in young adults infected perinatally or during childhood. Aids, 2019, 33, 1705-1710.	2.2	19
62	Maladaptative Autophagy Impairs Adipose Function in Congenital Generalized Lipodystrophy due to Cavin-1 Deficiency. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2892-2904.	3.6	17
63	An intercomparison of total column-averaged nitrous oxide between ground-based FTIR TCCON and NDACC measurements at seven sites and comparisons with the GEOS-Chem model. Atmospheric Measurement Techniques, 2019, 12, 1393-1408.	3.1	17
64	What have we learned form monogenic forms of severe insulin resistance associated with PCOS/HAIRAN?. Annales D'Endocrinologie, 2010, 71, 222-224.	1.4	16
65	EPHX1 mutations cause a lipoatrophic diabetes syndrome due to impaired epoxide hydrolysis and increased cellular senescence. ELife, 2021, 10, .	6.0	16
66	Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART. Journal of Lipid Research, 2015, 56, 692-702.	4.2	15
67	LMNA-associated partial lipodystrophy: anticipation of metabolic complications. Journal of Medical Genetics, 2017, 54, 413-416.	3.2	15
68	Clinical Utility Gene Card for: Familial partial lipodystrophy. European Journal of Human Genetics, 2017, 25, 271-271.	2.8	14
69	Congenital Generalized Lipoatrophy (Berardinelli-Seip Syndrome) Type 1: Description of Novel AGPAT2 Homozygous Variants Showing the Highly Heterogeneous Presentation of the Disease. Frontiers in Endocrinology, 2020, 11, 39.	3.5	14
70	Laminopathiesâ€™ Treatments Systematic Review: A Contribution Towards a â€˜Treatabolomeâ€™. Journal of Neuromuscular Diseases, 2021, 8, 419-439.	2.6	13
71	AdherenceÂwith metreleptin therapy and health self-perception in patients with lipodystrophic syndromes. Orphanet Journal of Rare Diseases, 2019, 14, 177.	2.7	12
72	Biallelic CAV1 null variants induce congenital generalized lipodystrophy with achalasia. European Journal of Endocrinology, 2021, 185, 841-854.	3.7	12

#	Article	IF	Citations
73	Adipocyte dysfunction in response to antiretroviral therapy: clinical, tissue and in-vitro studies. Current Opinion in HIV and AIDS, 2007, 2, 268-273.	3.8	11
74	A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies. European Journal of Endocrinology, 2021, 185, 453-462.	3.7	11
75	One-year metreleptin therapy decreases PCSK9 serum levels in diabetic patients with monogenic lipodystrophy syndromes. Diabetes and Metabolism, 2017, 43, 275-279.	2.9	10
76	Looking at New Unexpected Disease Targets in LMNA-Linked Lipodystrophies in the Light of Complex Cardiovascular Phenotypes: Implications for Clinical Practice. Cells, 2020, 9, 765.	4.1	10
77	Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Realâ€life experience from a national reference network. Diabetes, Obesity and Metabolism, 2022, 24, 1565-1577.	4.4	10
78	Peroxisome proliferatorâ€activated receptor gammaâ€ligandâ€binding domain mutations associated with familial partial lipodystrophy type 3 disrupt human trophoblast fusion and fibroblast migration. Journal of Cellular and Molecular Medicine, 2020, 24, 7660-7669.	3.6	9
79	Overlapping phenotypes between SHORT and Noonan syndromes in patients with PTPN11 pathogenic variants. Clinical Genetics, 2020, 98, 10-18.	2.0	9
80	Diagnosis, risk factors and management of diabetes mellitus in HIV-infected persons in France: A real-life setting study. PLoS ONE, 2021, 16, e0250676.	2.5	8
81	Irisin levels in LMNA-associated partial lipodystrophies. Diabetes and Metabolism, 2019, 45, 67-75.	2.9	6
82	Loss of thymidine phosphorylase activity disrupts adipocyte differentiation and induces insulin-resistant lipoatrophic diabetes. BMC Medicine, 2022, 20, 95.	5.5	6
83	Hypoglycaemia revealing heterozygous insulin receptor mutations. Diabetes and Metabolism, 2017, 43, 95-96.	2.9	5
84	Two Decades after Mandibuloacral Dysplasia Discovery: Additional Cases and Comprehensive View of Disease Characteristics. Genes, 2021, 12, 1508.	2.4	5
85	Cardiovascular complications of lipodystrophic syndromes â€“ focus on laminopathies. Annales D'Endocrinologie, 2021, 82, 146-148.	1.4	3
86	Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.7	3
87	Autoimmune hypoglycemia expands the biological spectrum of HHV8+ multicentric Castleman disease. Blood Advances, 2021, 5, 1848-1852.	5.2	2
88	Une brÃ¨ve histoire des laminopathies. Medecine Des Maladies Metaboliques, 2008, 2, 382-387.	0.1	1
89	Diabetes Mellitus, Extreme Insulin Resistance, and Hypothalamic-Pituitary Langerhans Cells Histiocytosis. Case Reports in Endocrinology, 2019, 2019, 1-8.	0.4	1
90	Les lipodystrophies et les troubles mÃ©taboliques associÃ©s Ã lâ€™infection par le VIH et Ã son traitementÂ: donnÃ©es actuelles. Medecine Des Maladies Metaboliques, 2008, 2, 573-578.	0.1	0

#	Article	IF	Citations
91	THU0569â€…Bone Imaging Findings in Genetic and Acquired Lipodystrophic Syndromes: A Retrospective Study of 24 Cases. Annals of the Rheumatic Diseases, 2015, 74, 406.2-406.	0.9	0
92	DonnÃ©es physiopathologiques et thÃ©rapeutiques rÃ©centes sur les syndromes lipodystrophiques. Medecine Des Maladies Metaboliques, 2018, 12, 642-649.	0.1	0
93	Lipides ectopiques et insulino-rÃ©sistance. Medecine Des Maladies Metaboliques, 2019, 13, 612-616.	0.1	0
94	Lipodystrophie et lipoatrophie. , 2021, , 333-339.		0
95	Organisation de la filiÃ¨re de prise en charge des lipodystrophies au niveau national. Medecine Des Maladies Metaboliques, 2021, 15, 149-156.	0.1	0
96	Lipodystrophies gÃ©nÃ©tiques partielles, de la physiopathologie Ã la prise en charge. Medecine Des Maladies Metaboliques, 2021, 15, 171-178.	0.1	0
97	Nitrous Oxide Profiling from Infrared Radiances (NOPIR): Algorithm Description, Application to 10 Years of IASI Observations and Quality Assessment. Remote Sensing, 2022, 14, 1810.	4.0	0